prove

(R)-Terazosin 是一种 Terazosin 的活性 R 型对映体, 是 α1-肾上腺素受体拮抗剂，对 α1a，α1b 和α1d-肾上腺素受体的Ki 分别为 6.51 nM，1.01 nM 和 1.97 nM。

Dipiproverine 是α-氨基酸酯类化合物，是一种解痉化合物。它被用作抗胆碱能药物。

Dipiproverine 是 Dipiproverine 的盐酸盐形式。Dipiproverine 是α-氨基酸酯类化合物，一种解痉化合物，它被用作抗胆碱能药物。

Musk ketone 可诱导癌细胞生长抑制和凋亡。它增加谷胱甘肽 S-转移酶的活性，因此可能被证明是有用的癌症化学保护剂。

GW-3333 is an matrix metalloproteinase inhibitor. It is also a tumor necrosis factor-alpha (TNF)-Converting Enzyme (TACE) inhibitor. The efficacy of GW3333 suggests that dual inhibitors of matrix metalloproteinases and TACE may prove therapeutic as antiar

LY 113174, a novel nonsteroidal aromatase inhibitor, may prove useful in the treatment of estrogen-dependent diseases.

CGC 11093 is a polyamine analog; inhibits growth of human prostate tumor xenografts in nude mice. It may prove useful in promoting regression of choroidal neovascularization.

Perfluorinated SAHA is an HDAC inhibitor for use in cancer treatment regimens, with demonstrated greater antiproliferative properties than SAHA . PFSAHA has also been shown to have higher selectivity for PA3774, an HDAC-like enzyme from P. aeruginosa, as well as other HDACs, which may prove beneficial for developing novel chemotherapeutic treatments for cancer.

Duartin is an anti-rickettsial compound. These small molecules and the workflow, featuring a high-throughput phenotypic screen for growth inhibitors of intracellular Rickettsia spp. and machine learning models for the prediction of growth inhibition of an obligate intracellular Gram-negative bacterium, should prove useful in the search for new therapeutic strategies to treat infections from Rickettsia spp. and other obligate intracellular bacteria.

Pinusolide is a platelet activating factor ( PAF) antagonist, it may prove of therapeutic value in the treatment of hypotension, it has antileukemic potential, and could be used to treat neurodegenerative diseases. Pinusolide attenuates blockade of insulin signaling by enhancing IRS-1 tyrosine phosphorylation by the activating the AMPK pathway, indicates the targeting of AMPK represents a new therapeutic strategy for hyperglycemia-induced insulin resistance and type 2 diabetes.

This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3 HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in